Therapeutic drug monitoring (TDM) has emerged as a strategy for treatment optimization in
inflammatory bowel diseases to maximize benefit and to reach more stringent, objective end …

The COVID-19 pandemic has raised considerable concerns that patients with inflammatory
bowel disease (IBD), particularly those treated with immunosuppressive therapies, may …

Breaking through the biologic therapy efficacy plateau for inflammatory bowel disease
requires the strategic development of personalized biomarkers in the tight control model …

Introduction Less than 50% of patients with inflammatory bowel diseases (IBD) receiving
monoclonal antibody (mAb) therapy achieve endoscopic remission. Poor outcomes may …

Apart from the Norwegian Drug Monitoring study (NORDRUM) B study, prospective
therapeutic drug monitoring (TDM) studies have largely failed to show the benefit of TDM for …

Introduction Therapeutic drug monitoring (TDM) is useful for optimizing monoclonal
antibodies (mAbs) for the treatment of immune-mediated inflammatory disorders including …

Background Therapeutic drug monitoring provides important guidance for treatment of
patients with inflammatory bowel disease (IBD) and could help to early identify treatment …

Renal transplant patients require regular monitoring of graft function and Tacrolimus levels.
This is thrice-weekly post-operatively, and those 1 year post-transplant are reviewed 3–6 …

Objective Why about a quarter of patients with inflammatory bowel disease (IBD) suffer
symptoms for more than a year before their diagnosis made is unclear. Low public …

'Science is about rejecting hypotheses, not confirming them.'Just like that, TAXIT, TAILORIX,
and NOR-DRUM cannot be considered evidence for a 'lack of benefit'of therapeutic drug …